Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK) · developed by Genzyme
Rilzabrutinib is an oral, covalent, reversible kinase inhibitor of Bruton's tyrosine kinase (BTK). It reduces B cell activation and autoantibody generation and blocks Fcγ receptor-mediated phagocytosis of antibody-coated cells. It is studied in immune thrombocytopenia and Graves' disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 26, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07216079 | Phase 3 | Immune Thrombocytopenia | Active not recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Graves' DiseaseImmune Thrombocytopenia
Updated Nov 15, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →